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Available online 21 November 2016Background:A uniﬁed set of criteria for neurocysticercosis (NCC) has helped to standardize its diagnosis in differ-
ent settings.
Methods: Cysticercosis experts were convened to update current diagnostic criteria for NCC according to two
principles: neuroimaging studies are essential for diagnosis, and all other information provides indirect evidence
favoring the diagnosis. Recent diagnostic advances were incorporated to this revised set.
Results: This revised set is structured in absolute, neuroimaging and clinical/exposure criteria. Absolute criteria
include: histological conﬁrmation of parasites, evidence of subretinal cysts, and demonstration of the scolex
within a cyst. Neuroimaging criteria are categorized as major (cystic lesions without scolex, enhancing lesions,
multilobulated cysts, and calciﬁcations), conﬁrmative (resolution of cysts after cysticidal drug therapy, spontane-
ous resolution of single enhancing lesions, and migrating ventricular cysts on sequential neuroimaging studies)
and minor (hydrocephalus and leptomeningeal enhancement). Clinical/exposure criteria include: detection of
anticysticercal antibodies or cysticercal antigens by well-standardized tests, systemic cysticercosis, evidence of
a household Taenia carrier, suggestive clinical manifestations, and residency in endemic areas. Besides patients
having absolute criteria, deﬁnitive diagnosis can be made in those having two major neuroimaging criteria (or
one major plus one conﬁrmative criteria) plus exposure. For patients presenting with one major and one
minor neuroimaging criteria plus exposure, deﬁnitive diagnosis of NCC requires the exclusion of confounding pa-
thologies. Probable diagnosis is reserved for individuals presenting with one neuroimaging criteria plus strong
evidence of exposure.
Conclusions: This revised set of diagnostic criteria provides simpler deﬁnitions andmay facilitate itsmoreuniform
and widespread applicability in different scenarios.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Despite being caused by a well-known infective agent – the
encysted larval stage of the pork tapeworm Taenia solium – the diag-
nosis of neurocysticercosis (NCC) is complicated because histological
demonstration of the parasites is not possible, as surgical resection of
the lesion is not indicated inmost cases. During the second half of the
20th century, introduction of modern neuroimaging techniques and
development of immunological tests enhanced the diagnostic accu-
racy for NCC by allowing visualization of parasites within the central
nervous system and demonstrating speciﬁc host antibodies and par-
asite antigens [1]. Nevertheless, the diagnosis remained problematic
as neuroimaging ﬁndings are rarely pathognomonic and immunodi-
agnostic tests vary in sensitivity and speciﬁcity [2,3]. An initial pro-
posal for a set of diagnostic criteria for human cysticercosis (both
systemic cysticercosis and NCC) based on the objective evaluation
of clinical, radiologic, immunologic, and epidemiologic data was
published in 1996 [4]. An updated version was proposed in 2001,
conﬁned to the diagnosis of NCC [5]. Both sets used the same basic
structure, that is, four categories of diagnostic criteria (absolute,
major, minor and epidemiologic) stratiﬁed according to their diag-
nostic strength, and different degrees of diagnostic certainty based
on the likelihood that the disease is present in a given patient.
These criteria have proved useful for NCC diagnosis in both hospital
and ﬁeld settings, have been widely used in endemic as well as in
non-endemic areas [6], and have recently been validated by an ex-
ternal group, with a sensitivity of 93.6% and a speciﬁcity of 81.1%
for the diagnosis of NCC [7]. Here, we present a revised version of
the set of diagnostic criteria for NCC, updated to provide simpler
and more operational deﬁnitions, as well as to incorporate advances
and insights that have improved the diagnosis in recent years.2. Conceptual basis for updates and modiﬁcations
As was the case in the 2001 set of diagnostic criteria, this revised
version is designed for the diagnosis of NCC, because – with few
exceptions – subcutaneous, muscular or other forms of systemic
cysticercosis are not signiﬁcant medical problems. A second guiding
principle was to ensure its worldwide applicability, irrespective
of the reported regional differences in the forms of presentation or
NCC.2.1. Methodology
A panel of experts in human cysticercosis was convened, including
neurologists, neurosurgeons, neuroradiologists, parasitologists, infec-
tious disease specialists and epidemiologists from Latin America, the In-
dian subcontinent, and the United States (US). An initial step identiﬁed
criteria that were unanimously considered appropriate and selected
those targeted for modiﬁcation or exclusion. Relevant literature on re-
cent advances in the diagnosis of this disease was independently
reviewed by panel members. The opinions of each of the experts were
used to draft a modiﬁed version of the diagnostic criteria chart. Discrep-
ancies were resolved by discussion and consensus. As the primary focus
of this manuscript was not to report the ﬁndings of an accuracy study,
schemes such as the STARD guidelines [8] were not used.
2.2. Overview of major modiﬁcations
While the category of absolute diagnostic criteria remains essentially
unchanged in this revised version, the structure of the remaining cate-
gories wasmodiﬁed in accordance with to twomain principles: 1) neu-
roimaging studies are essential for the diagnosis of NCC; and 2)
information from clinical manifestations, immunodiagnostic tests and
epidemiologic settings only provides indirect evidence favoring the di-
agnosis of NCC. Therefore, instead of having categories of major, minor
and epidemiologic criteria, where different types of criteria were
grouped according to their individual diagnostic strength, we now use
neuroimaging signatures of NCC on one side and clinical/exposure evi-
dence for cysticercosis on the other. As a result, the requirements for a
case being classiﬁed as “deﬁnitive” or “probable” NCC changed accord-
ing to these principles (Table 1).
3. Revised diagnostic criteria
3.1. Absolute diagnostic criteria
These criteria provide unequivocal evidence of the presence of cysti-
cerci infection of the central nervous system (Fig. 1).
3.1.1. Histological demonstration of the parasite from biopsy of a brain or
spinal cord lesion
Visualization of histopathological characteristics of cysticerci in bi-
opsy material, including the spiral canal and the rostellum with its
Table 1
Revised diagnostic criteria and degrees of diagnostic certainty for neurocysticercosis.
Diagnostic criteria
Absolute criteria:
• Histological demonstration of the parasite from biopsy of a brain or spinal cord
lesion.
• Visualization of subretinal cysticercus.
• Conclusive demonstration of a scolex within a cystic lesion on neuroimaging
studies.
Neuroimaging criteria:
Major neuroimaging criteria:
• Cystic lesions without a discernible scolex.
• Enhancing lesions.a
• Multilobulated cystic lesions in the subarachnoid space.
• Typical parenchymal brain calciﬁcations.a
Conﬁrmative neuroimaging criteria:
• Resolution of cystic lesions after cysticidal drug therapy.
• Spontaneous resolution of single small enhancing lesions.b
• Migration of ventricular cysts documented on sequential neuroimaging studies.a
Minor neuroimaging criteria:
• Obstructive hydrocephalus (symmetric or asymmetric) or abnormal enhance-
ment of basal leptomeninges.
Clinical/exposure criteria:
Major clinical/exposure:
• Detection of speciﬁc anticysticercal antibodies or cysticercal antigens by well--
standardized immunodiagnostic tests.a
• Cysticercosis outside the central nervous system.a
• Evidence of a household contact with T. solium infection.
Minor clinical/exposure:
• Clinical manifestations suggestive of neurocysticercosis.a
• Individuals coming from or living in an area where cysticercosis is endemic.a
Degrees of diagnostic certainty
Deﬁnitive diagnosis:
• One absolute criterion.
• Two major neuroimaging criteria plus any clinical/exposure criteria.
• One major and one conﬁrmative neuroimaging criteria plus any clinical/-
exposure criteria.
• One major neuroimaging criteria plus two clinical/exposure criteria (including
at least one major clinical/exposure criterion), together with the exclusion of
other pathologies producing similar neuroimaging ﬁndings.
Probable diagnosis:
• One major neuroimaging criteria plus any two clinical/exposure criteria.
• One minor neuroimaging criteria plus at least one major clinical/exposure
criteria.
a Operational deﬁnitions. Cystic lesions: rounded, well deﬁned lesions with liquid con-
tents of signal similar to that of CSF on CT or MRI; enhancing lesions: single or multiple,
ring- or nodular-enhancing lesions of 10–20 mm in diameter, with or without surround-
ing edema, but not displacing midline structures; typical parenchymal brain calciﬁcations:
single or multiple, solid, and most usually b10 mm in diameter; migration of ventricular
cyst: demonstration of a different location of ventricular cystic lesions on sequential CTs
or MRIs; well-standardized immunodiagnostic tests: so far, antibody detection by enzyme-
linked immunoelectrotransfer blot assay using lentil lectin-puriﬁed T. solium antigens,
and detection of cysticercal antigens by monoclonal antibody-based ELISA; cysticercosis
outside the central nervous system: demonstration of cysticerci from biopsy of subcutane-
ous nodules, X-ray ﬁlms or CT showing cigar-shape calciﬁcations in soft tissues, or visual-
ization of the parasite in the anterior chamber of the eye; suggestive clinical manifestations:
mainly seizures (often starting in individuals aged 20–49 years; the diagnosis of seizures
in this context is not excluded if patients are outside of the typical age range), but other
manifestations include chronic headaches, focal neurologic deﬁcits, intracranial hyperten-
sion and cognitive decline; cysticercosis-endemic area: a placewhere active transmission is
documented.
b The use of corticosteroids makes this criterion invalid.
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NCC [9]. In many subarachnoid cysts, the scolex cannot be identiﬁed
but the typical three-layered membrane wall often allows the correct
identiﬁcation of the parasite. However, a problem arises when biopsy
material comes from calciﬁed or even granular cysticerci since the sco-
lex and membranes may not be present in these stages of involution of
parasites. In such cases, the presence of the so-called calcareous corpus-
clesmay help to identify the parasitic (cestode) nature of the lesion [10].
3.1.2. Visualization of subretinal cysticercus
Fundoscopic examination revealing the characteristic appearance of
subretinal cysticerci allows deﬁnitive diagnosis of NCC as the retina is
part of the central nervous system [11,12]. These lesions are unusual,
even in endemic areas, and may or may not be associated with cerebral
lesions. Of note, individualswith cysticerci located in the anterior cham-
ber of the eye should not be considered to have NCC but cysticercosis
outside the nervous system.
3.1.3. Conclusive demonstration of a scolex within a cystic lesion on neuro-
imaging studies
These lesions were described in the ﬁrst reports of neuroimaging
ﬁndings of NCC, and are known to represent living parenchymal, small
subarachnoid or ventricular cysticerci [13,14]. Parenchymal cysts tend
to develop at the cortical-subcortical junction and the basal ganglia,
and less often located in the brainstem, cerebellum or the spinal cord
parenchyma. Subarachnoid cysts showing the scolex are often those lo-
cated within cortical sulci at the convexity of cerebral hemispheres, and
ventricular cysts may be located within any ventricular cavity.
Signal properties of the scolex components allow its brilliant appear-
ance on CT and MRI, producing the so-called “hole-with-dot” imaging
that has long been reported as pathognomonic of NCC [14]. New proto-
cols such as diffusion weighted images (DWI) and fast imaging
employing steady-state acquisition (FIESTA) may enhance the diagnos-
tic accuracy of MRI as they allow the recognition of the scolex in cases
that are not visualized with conventional sequences [15,16] (Fig. 2).
Nevertheless, some cystic tumors may have remnants of neoplastic
cells in the interior of the cystic component resembling a scolex. This
note of caution is particularly important for individuals with single
cysts (Fig. 3). In other cases, debris within a cystic lesion from unrelated
etiologies may have the appearance of a scolex on a single imaging cut.
Doubtful cases should be reviewed by expert readers taking into ac-
count not only the bright dot in the interior of the lesion, but the char-
acteristics of the cyst including size, shape and wall contours, as well
as the pattern of enhancement around the lesion.Most viable parenchy-
mal brain cysticerci are b20mm in diameter, round and clearly demar-
cated from the surrounding brain parenchyma, and do not signiﬁcantly
enhance after contrast medium administration.
3.2. Neuroimaging criteria
Some neuroimaging signatures of NCC strongly suggest the diagnosis
but should not be used by themselves to conﬁrm the presence of the dis-
ease (Fig. 4). In the present version, neuroimaging criteria are separately
considered to reﬂect the importance of their combination for reaching a
deﬁnitive diagnosis of NCC. Nevertheless, it must be kept in mind that
several other conditions may cause this type of lesions and a diagnostic
work-up attempting to discard alternative pathologies is advised.
3.2.1. Major neuroimaging criteria
This group includes lesions highly suggestive of NCC on CT or MRI
that, nonetheless, cannot be used by themselves to conﬁrm or exclude
the disease. They include: cystic lesionswithout a discernible scolex, en-
hancing lesions,multilobulated cystic lesions in the subarachnoid space,
and typical parenchymal brain calciﬁcations. Of importance, the pres-
ence of two different lesions signiﬁcantly increases the likelihood of a
deﬁnitive diagnosis of NCC in a given patient.
Fig. 1. Absolute diagnostic criteria for neurocysticercosis. Upper panel shows biopsy ﬁndings with the characteristic rostellum of Taenia solium (large arrows) and three-layered
membranes observed in racemose cysticerci (small arrows). Lower panel shows the typical appearance of subretinal cysticercus (arrowheads) and the “hole-with-dot” imaging
produced by the scolex (white arrows).
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round, cystic, ﬂuid ﬁlled lesions b20mm in diameter without a discern-
ible scolex. These lesions may be single or multiple and may be located
in the brain or spinal cord parenchyma, the subarachnoid space over the
convexity of cerebral hemispheres, or within the ventricular cavities.
These lesions are often well demarcated from the surrounding cerebral
tissues and most of them do not show abnormal enhancement after
contrast medium administration [17]. When cysts are multiple andFig. 2. Diffusion-weighted image (left) and fast imaging employing steady-state acquisitiolocated in the brain parenchyma and/or in subcortical sulci between
two cerebral convolutions, they give the brain a “Swiss cheese” appear-
ance, which is fairly characteristic of NCC [18].
3.2.1.2. Enhancing lesions. This category includes some of the most com-
mon, but at the same time less speciﬁc, neuroimaging signatures of NCC
[19]. These lesions are usually b20 mm in diameter and display en-
hancement in a ring or nodular pattern after contrast mediumn (right) MRI sequences showing the scolex inside vesicular cysticerci (arrowheads).
Fig. 3. Scolex mimic in a patient with adenocarcinoma and brain metastasis.
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but rarely displace midline structures [20]. Some of themmay have im-
aging evidence of a cystic cavity ﬁlled with ﬂuid while others appear
more ill-deﬁned and compact. These lesions may be single or multiple
and may be located in the brain or spinal cord parenchyma, or in the
subarachnoid space over the convexity of cerebral hemispheres [19–
21]. Cysts within the ventricular cavities may also present with abnor-
mal enhancement if they are attached to the ventricular lining [19]. To
be included into this category, patients with enhancing lesions should
fulﬁll the criteria of Rajshekhar & Chandy (seizures as presenting com-
plaint; no evidence of persistent raised intracranial pressure, progres-
sive neurological deﬁcit or an active systemic disease, and a solitary
contrast enhancing lesion measuring 20 mm or less in its maximal di-
mension without a shift of the midline structures due to the surround-
ing edema) [20].3.2.1.3. Multilobulated cystic lesions in the subarachnoid space. Cysticerci-
related cystic lesionsmay attain a large size especially when they are lo-
catedwithin the Sylvian ﬁssure, subarachnoid cisterns at the base of the
brain and the spinal canal [17,22,23]. In these cases – corresponding to
the time-honored description of racemose cysticercosis [24]– the scolex
is usually not discernible on neuroimaging studies (or even at biopsy,
where only degenerated membranes can be seen) as it has been
destroyed as the result of a process of hydropic degeneration [9,19].
Large subarachnoid cysts often adopt a multilobulated appearance due
to the conﬂuence of vesicles together with inﬂamed arachnoidFig. 4.Major neuroimaging criteria for neurocysticercosis, including: cystic lesion without di
subarachnoid cisterns (center right) and typical parenchymal brain calciﬁcations (right).membranes; this imaging resembling a “bunch of grapes” is highly sug-
gestive of NCC [23].
3.2.1.4. Typical parenchymal brain calciﬁcations. This is themost common
neuroimaging signature of NCC, particularly in areas where the disease
is highly endemic [25]. Epidemiological evidence as well as follow up
imaging studies in patients after resolution of viable cysticercosis dem-
onstrate typical calciﬁed lesions, different in shape, size and distribution
to brain calciﬁcations resulting from other pathologies. Cysticerci-relat-
ed calciﬁcations are solid, most often b10mm in diameter and are even-
ly distributed in the brain parenchyma with the exception of the
brainstem and cerebellum, where they are rare. These small, rounded,
well-deﬁned calciﬁcations are infrequent if ever found in patients
from non cysticercosis-endemic countries, where calciﬁcations due to
many other physiological or pathological mechanisms have distinct ap-
pearances and shapes [26,27]. While modern sequences such as T2-
weighted gradient-echo and diffusion tensor imaging have increased
the ability of MRI to recognize mineralization, CT should be the optimal
screening procedure to visualize calciﬁcation and quantify these lesions
and to reduce the risk of confusing them with cerebral microbleeds,
which is a common unrelated neuroimagingﬁnding in older individuals
[28]. On CT, the presence of multiple calciﬁcations gives the brain a
“starry night” appearance, which is highly suggestive of NCC.
3.2.2. Conﬁrmative neuroimaging criteria (on follow-up)
For patients presenting with any of the previously described cystic
lesions, resolution or transformation into a calciﬁed nodule after a trial
with either albendazole or praziquantel [29], in the absence of any
other speciﬁc medical treatment, should be considered as a criteria pro-
viding robust support for NCC diagnosis. In addition, in the subset of pa-
tients presenting with a small enhancing lesion fulﬁlling the imaging
criteria of Rajshekhar & Chandy [20], spontaneous disappearance of
these lesions should also be considered as a proof of NCC diagnosis
[30,31]. Spontaneous resolution of single enhancing lesions has long
been recognized as a conﬁrmation of NCC [32], and is not expected to
occur in the most frequent potential differential diagnoses such as tu-
berculosis, toxoplasmosis, malignancy or pyogenic cerebral abscess. It
must be kept in mind that corticosteroids are often used as the single
therapeutic approach to patients with small enhancing lesions [33].
Since corticosteroids may also favor the resolution of enhancing lesions
fromunrelated causes (i.e., primary cerebral lymphoma), their adminis-
tration preclude the use of this particular criterion to conﬁrm NCC
diagnosis.
Another conﬁrmative neuroimaging criteria is the demonstration,
on sequential neuroimaging studies, of migration of cystic lesions
from one ventricular cavity to another (i.e., from the III to the IV ventri-
cle through the cerebral aqueduct), or even within the same cavity (i.e.,scernible scolex (left), ring-enhancing lesions (center left), multilobulated cysts in basal
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anterior to the posterior aspects of the III ventricle). This migrationmay
occur when cysts are freely-ﬂoating within the ventricular system and,
although rare, is virtually pathognomonic of NCC [34–37].
3.2.3. Minor neuroimaging criteria
These criteria refer to lesions compatible with NCC on neuroimaging
studies, including obstructive hydrocephalus (symmetrical or asym-
metrical) and focal or diffuse abnormal enhancement of the
leptomeninges at the base of the brain. These ﬁndings provide addition-
al support for the diagnosis of NCC in patients with a single major neu-
roimaging criterion but, by themselves, are non-speciﬁc as they are
often observed in other infectious and non-infectious diseases of the
nervous system. In this scenario, cytochemical analysis of CSF may pro-
vide diagnostic clues thatmust be interpreted on the light of the clinical
manifestations and the results of other complementary exams.
3.3. Clinical/exposure criteria
All criteria included under this category refer to ﬁndings strongly fa-
voring or conﬁrming the diagnosis of cysticercosis, which may not nec-
essarily be located in the nervous system. As previously noticed, the
presence of any of them should only be used as a circumstantial evi-
dence favoring the diagnosis of NCC.
3.3.1. Detection of speciﬁc anticysticercal antibodies or cysticercal antigens
by well-standardized immunodiagnostic tests
The enzyme-linked immunoelectrotransfer blot (EITB) assay using
lentil lectin-puriﬁed glycoprotein extracts is the most reliable test for
the detection of antibodies speciﬁc for T. solium antigens in serum or
CSF [38]. This EITB has a speciﬁcity approaching 100% and a sensitivity
of 98% for individuals with two ormore viable or degenerating parasites
[39], although a single positive reaction with the 50 kDa protein occa-
sionally represents a false-positive result [40]. Furthermore, a positive
EITB does not conﬁrm CNS infection since it demonstrates a systemic
antibody response. It should be taken into account that in endemic re-
gions there is a sizable positive background seroprevalence of 5–20%,
usually with weak reactions to one or a few bands [25]. Another limita-
tion of the EITB is its low sensitivity in patients with single intracranial
cysticerci and in those with only calciﬁed parasites, where up to 50%
of cases may be falsely negative [41,42].
The use of a monoclonal antibody (MAb)-based ELISA for detection
of cysticercal antigen in serum or CSF reﬂects the presence of viable par-
asites and has been reported to be very useful, particularly in the follow
up of NCC patients [43]. The sensitivity of this test has not been assessed
in detail, although it seems lower than antibody tests in patients with
one or a few lesions [38]. This assay is nearly always negative in individ-
uals with calciﬁed parasites only. While it does not seem to cross-react
with any of the other known human cestode infections, interpretation
of a positive test is likely affected by the selection of a lower (less specif-
ic) or higher cut-off. So far, the high numbers of antigen-positive indi-
viduals in community-based studies in Africa have not been
systematically conﬁrmed by brain imaging [44].
Some time-honored tests, such as anticysticercal antibody detection
by ELISA in CSF samples [45], have shown to be reliable for the diagnosis
of some forms of NCC and are still used as a diagnostic tool in areaswith
limited access to the EITB assay. However, the multiplicity of crude and
semi-puriﬁed antigens used in diverse assays in the absence of veriﬁca-
tion and standardization does not allow a general acceptance of its use
[46]. Although some ELISAs using new antigens are reported in the liter-
ature, none of these assays is commercially available; on the contrary,
published examples demonstrate how cross reactions in ELISA may
lead to wrong diagnoses and worsen the patient's prognosis [47,48].
Therefore, at the present time antibody-detection by ELISA should not
be included as a diagnostic criterion.3.3.2. Cysticercosis outside the nervous system
The presence of extraneural cysticercosis requires histological dem-
onstration of the parasite from biopsy of a subcutaneous nodule, plain
X-ray ﬁlms or CT scans showing multiple “cigar-shaped” calciﬁcations
in thigh and calf muscles, or direct visualization of a cysticercus in the
anterior chamber of the eye.
3.3.3. Evidence of a household contact with T. solium infection
The ﬁnding of a Taenia carrier in the patient's close environment is
now considered highly suggestive of exposure in light of robust evi-
dence showing cysticercosis is commonly transmitted from human-
to-human and clustered in households [49]. Indeed, compulsory search
of Taenia carriers amonghousehold contacts of NCC patients is currently
advised to identify the potential source of infection, and to reduce fur-
ther spread of the disease [38].
3.3.4. Presence of clinical manifestations suggestive of NCC
Symptomatic NCC patients often present with non-speciﬁc ﬁndings
that might not be used as a strong argument favoring the diagnosis. Sei-
zures are the most common manifestation, occurring in 70% of symp-
tomatic cases [50] and are frequently of late onset (in most cases
symptoms begin between 20 and 49 years of age) [51], although they
may occur at any age. However, even in this age range, there are a
number of alternative causes of seizures. Other clinical manifestations
of the disease include headache, focal neurologic deﬁcits, intracranial
hypertension, and cognitive decline. The prevalence of NCC-related
headache and cognitive decline are largely unknown. Focal neurological
signs are uncommon and depend on the location of parasites in the ner-
vous system or the occurrence of a cysticercosis-related stroke, and in-
tracranial hypertension is mainly conﬁned to individuals with
hydrocephalus, cysticercotic encephalitis and to those with large sub-
arachnoid or ventricular cysts [52,53]. Of interest, fever, sweats and
weight loss are uncommon manifestation of NCC and its presence
should suggest other diagnoses. In addition, the ﬁndings of adenopathy
suggest an alternative diagnosis such as a tumor or another infection.
3.3.5. Individuals coming from or living in cysticercosis-endemic areas
Caution must be exerted when applying this criterion to avoid over-
diagnosis just because a person has lived in a country where the disease
is common. Endemic areas for cysticercosis should be deﬁned as those
places where the life cycle of Taenia solium can be fully completed, as
all the inter-related steps needed for its completion are present [54]. It
is well known that evenwithin the same country, endemicity of the dis-
ease varies between urban centers and rural villages [55].
4. Degrees of diagnostic certainty
As previously noticed, evidence needed to reach diagnostic catego-
ries of “deﬁnitive” and “probable” have been modiﬁed according to
the changes made in diagnostic criteria.
4.1. Deﬁnitive diagnosis
Besides individuals having one absolute criterion, this revised set al-
lows this degree of diagnostic certainty in people having at least two
major neuroimaging criteria (or one major plus one conﬁrmative neu-
roimaging criteria) plus any clinical/exposure criteria. For patients pre-
senting with one major criterion (associated or not with one minor
neuroimaging criteria) plus evidence of exposure, deﬁnitive diagnosis
of NCC requires a complete work-up to exclude confounding
pathologies.
4.2. Probable diagnosis
This category includes individuals presenting with only one type of
major or minor neuroimaging criteria plus strong evidence of exposure
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agnosis can be entertained in individuals who have not undergone neu-
roimaging studies yet, provided they have seizures plus at least two
other exposure criteria. Of importance, the presence of both a normal
CT andMRI should negate the diagnosis of NCC even if other clinical/ex-
posure criteria pointing to systemic cysticercosis are present. In the ab-
sence of neuroimaging, history of seizures plus at least two other
exposure criteria could suggest NCC, but the lack of neuroimaging
exams precludes clinical interventions beyond symptomatic measures.
5. Additional evaluations
After the submissionof the initial version of thismanuscript, a slight-
ly modiﬁed set of criteria was published by a separate group [7], and re-
ported to have similar sensitivity (93.2%) and speciﬁcity (81.4%) as the
2001 version of this set of criteria (sensitivity 93.6% and speciﬁcity
81.1% in the same report). Modiﬁcations from the previous version of
our criteria included the allocation of a separate category for
extraparenchymal NCC, and the inclusion of serum antibody detection
by ELISA in the same category than EITB, which has not been considered
appropriate [46].
To assess whether the current set could miss sensitivity for cases of
extraparenchymal NCC, we evaluated the records of 23 consecutive pa-
tients attending the general neurosurgery service of the Instituto
Nacional de Ciencias Neurológicas in Lima, Peru, whose pathology-con-
ﬁrmed diagnosis was subarachnoid NCC. All of them fulﬁlled the criteria
for deﬁnitive neurocysticercosis, on the basis of absolute criteria in ﬁve
cases (conclusive demonstration of a scolex in a cystic lesion), two
major neuroimaging criteria plus any clinical/exposure criteria in 15
cases (neuroimaging ﬁndings in this group included multilobulated
subarachnoid cystic lesions in all 15 cases, plus cystic lesions without
scolex in nine, and typical parenchymal brain calciﬁcations in 11 cases.
Clinical/exposure criteria included a positive LLGP-EITB and living in
an endemic area in all 15 cases, and clinical manifestations suggestive
of neurocysticercosis, either intracranial hypertension [n = 8], seizures
[n = 8] or motor deﬁcit [n = 1]), or one major neuroimaging criterion
plus two clinical exposure criteria in the three remaining cases (they
all had a subarachnoid cystic lesion, a positive LLGP-EITB, clinical man-
ifestations suggestive of NCC, and lived in a endemic area).We also con-
ducted a literature review looking for reported cases with surgical/
histopathological conﬁrmation of ventricular cysticercosis during the
past 20 years. A total of 21 papers describing 29 patients, where case de-
scriptions and neuroimaging ﬁndings were appropriately detailed as to
apply our set to diagnostic criteria, were found [35,37,56–74]. Despite
the fact that most of these patients did not had a serum EITB performed,
the set allowed a deﬁnitive pre-operative diagnosis of NCC in 23 cases
(one absolute criterion in 12, two major neuroimaging in six, and one
major neuroimaging plus one conﬁrmative in ﬁve), and a probable diag-
nosis in the remaining six patients.
Additionally, we evaluated two commercially available ELISA kits
(Ridascreen T. solium IgG, R-Biopharm, Darmstadt, Germany, and
NovaLisa T. solium IgG ELISA, Novatec, Hamburg, Germany) by assessing
30 samples of EITB-positive patients with calciﬁed NCC and 60 samples
of patients with other parasitic infections (30 with hydatid disease and
30 with hymenolepiasis, all seronegative for cysticercosis on EITB).
Compared to EITB, the sensitivity of ELISA antibody detection in patients
with calciﬁed NCC was poor for both kits (4/30, 13%, and 2/30, 7%), and
the frequency of cross-reactions with hydatid disease was high (26/30,
87%, and 18/30, 60%), with some cross-reactions to hymenolepiasis
samples (5/30, 17%, and 1/30, 3%). Detailed methods and results of
this serology evaluation will be published elsewhere.
6. Comment
This simpliﬁed revised set of diagnostic criteria may facilitate its
more uniform and widespread applicability in different clinicalscenarios and environments. Deﬁnitive diagnosis is now based on the
demonstration of one absolute criterion or accumulative evidence
supporting cysticercosis infection of the nervous system. Complementa-
ry testing is advised for the exclusion of alternative pathologies when
evidence provided by neuroimaging studies is not robust. Proper inter-
pretation of these criteria also requires a reasonable experience of
knowledge of the imaging appearance of NCC. This revised set also per-
mits a probable NCC diagnosis in individuals presenting with clinical
manifestations (mainly seizures) and exposure evidence of cysticercosis
who live in highly endemic underserved populations, where neuroim-
aging studies are not readily available. However, a deﬁnitive diagnosis
of NCC cannot be established without the aid of neuroimaging. Clini-
cians and researches involved in NCC diagnosis should be trained to un-
derstand the rationale of this revised set as well as its advantages and
potential limitations.
Additional information added post-facto demonstrated a very high
sensitivity of this modiﬁed version to diagnose subarachnoid NCC (23/
23, 100%; 95% conﬁdence interval: 85.7–100%) as well as ventricular
NCC (23/29, 79.3%; 95% conﬁdence interval: 61.6–90.2%), and also dem-
onstrated the poor performance of serum ELISA antibody detection,
conﬁrming our position that it should not be equaled to the LLGP-EITB
assay as has been suggested by others [7].
In an ideal scenario, this revised set would be validated to deﬁne its
accuracy, meaning that individuals falling in the category of deﬁnitive
NCC diagnosis must undergo invasive procedures to conﬁrm the infec-
tion or rule out alternative pathologies, and also a similar number of in-
dividuals with a negative NCC diagnosis should undergo these
procedures to prove the opposite. Obviously, this is not ethical or even
possible for most cases, although partial information can be obtained
from systematic long-term follow-up of patients with deﬁnitive diagno-
sis of NCC according to this set, that eventually arrive to a diagnosis
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